Lubiprostone, a constipation drug, has a kidney protective effect
Improvement of Intestinal Microbiota Improves Mitochondrial Function
Overview
Chronic kidney disease (CKD) is a major global health issue without any drugs that improve kidney function. Previous mouse experiments showed that lubiprostone, a constipation drug, reduces uremic toxin accumulation by improving the intestinal environment altered by kidney decline, thus inhibiting kidney damage progression 1.
A phase II clinical trial was conducted to test lubiprostone's effects on kidney function in patients. Results revealed dose-dependent suppression of kidney function decline (eGFR) in lubiprostone-treated patients compared to placebo. Further analysis showed lubiprostone improves kidney mitochondrial function by modulating the gut microbiota and increasing spermidine production, which enhances mitochondrial activity and provides kidney protection.
Lubiprostone has a kidney protective effect 2
Product Application
・Drug for treating CKD
・Drug for treating overall diseases associated with decreased mitochondrial function
Related Works
【1】 J Am Soc Nephrol. 2015 Aug;26(8):1787-94
【2】Lubiprostone in Chronic Kidney Disease: Insights into Mitochondrial Function and Polyamines from a Randomized Phase 2 Clinical Trial
DOI：https://doi.org/10.1126/sciadv.adw3934
IP Data
IP No. ： 63/814,436
Inventor ： ABE Takaaki, WATANABE Shun
keyword ： Lubiprostone, Chronic kidney disease（CKD）,drug repositioning,Improves Mitochondrial Function